Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients

European Journal of Haematology

Volumn 77, Issue 5, 2006, Pages 410-415

  Martino, Massimo ^a   Praticò, Giulia ^a   Messina, Giuseppe ^a   Irrera, Giuseppe ^a   Massara, Elisabetta ^a   Console, Giuseppe ^a   Iacopino, Pasquale ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

Autotransplant; Filgrastim; Myeloma; Neutropenia; Pegfilgrastim

Indexed keywords

ACICLOVIR; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; ITRACONAZOLE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTEREMIA; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; INFECTION; LEUKOCYTE; MALE; MULTIPLE DRUG DOSE; MULTIPLE MYELOMA; NEUTROPENIA; NEUTROPHIL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS INFECTION; STATISTICAL SIGNIFICANCE; STROKE; THROMBOCYTE LIFESPAN;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DACARBAZINE; FEMALE; FILGRASTIM; HEMATOPOIESIS; HUMANS; INFECTION; INFECTION CONTROL; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; NEUTROPENIA; NIMUSTINE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECOVERY OF FUNCTION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; VINCRISTINE;

EID: 33749261624     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2006.00736.x     Document Type: Article

References (30)

1. ATTAL M, HAROUSSEAU J-L, STOPPA A-M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-97.
2. BARLOGIE B, JAGANNATH S, DESIKAN KR, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
3. CHILD JA, MORGAN GJ, DAVIES FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
4. ATTAL M, HAROUSSEAU JL, FACON T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-2502.
5. HAAS PS, BAUCHMULLER K, KUHNEMUND A, FINKE J, IHORST G, ENGELHARDT M. Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period. Ann Hematol 2006;85:191-193.
6. BAROSI G, BOCCADORO M, CAVO M, CORRADINI P, MARCHETTI M, MASSAIA M, MERLINI G, TOSI P, TURA S. Italian society of hematology; Italian society of experimental hematology; Italian group for bone marrow transplantation. Management of multiple myeloma and related-disorders: guidelines from the Italian society of hematology (SIE), Italian society of experimental hematology (SIES) and Italian group for bone marrow transplantation (GIT-MO). Haematologica 2004;89:717-741.
7. WEAVER CH, SCHWARTZBERG LS, HAINSWORTH J, GRECO FA, LI W, BUCKNER CD, WEST WH. Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centres. Bone Marrow Transplant 1997;19:671-678.
8. SCHMITZ N, LJUNGMAN P, CORDONNIER C, et al. Lenograstim after autologous peripheral blood progenitor cell transplantation: results of a double blind, randomized trial. Bone Marrow Transplant 2004;34:955-962.
9. HORNEDO J, SOLA C, SOLANO C, LOPEZ JJ, ALONSO S, LLUCH A, OJEDA B, GARCIA-CONDE J, CORTES-FUNES H, SOLTI Group. The role of granulocyte colony stimulating factor (G-CSF) in the post-transplant period. Bone Marrow Transplant 2002;29:737-743.
10. DALLORSO S, RONDELLI R, MESSINA C, et al. Clinical benefits of granulocyte colony-stimulating factor therapy after haematopoietic stem cell transplant in children: results of a prospective randomized trial. Haematologica 2002;87:1274-1280.
11. BENCE-BRUCKLER I, BREDESON C, ATKINS H, MCDIARMID S, HAMELIN L, HOPKINS H, PERRY G, GENEST P, HUEBSCH L. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bone Marrow Transplant 1998;22:965-969.
12. MOLINEUX G, KINSTLER O, BRIDDELL B, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-1734.
13. MOLINEUX G. Pegylation: engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:3S-8S.
14. MOLINEUX G. The design and development of Pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). Curr Pharm Des 2004;10:1235-1244.
15. HOLMES FA, O'SHAUGHNESSY JA, VUKELJA S, et al. Blinded, randomized, multicenter study to evaluate single administration Pegfilgrastim once per cycle versus daily Filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731.
16. HOLMES FA, JONES SE, O'SHAUGHNESSY J, et al. Comparable efficacy and safety profiles of once-per-cycle Pegfilgrastim and daily injection Filgrastim in chemotherapyinduced neutropenia: a multicentre dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-909.
17. VOSE JM, CRUMP M, LAZARUS H, et al. Randomized, multicentre, open-label study of Pegfilgrastim compared with daily Filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-519.
18. STEIDL U, FENK R, BRUNS I, et al. Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2005;35:33-36.
19. GEORGE S, YUNUS F, CASE D, YANG BB, HACKETT J, SHOGAN JE, MEZA LA, NEUMANN TA, LIANG BC. Fixed-dose Pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-1996.
20. JOHNSTON E, CRAWFORD J, BLACKWELL S, et al. Randomized, dose-escalation study of SD/01 compared with daily Filgrastim in patients receiving chemotherapy. J Clin Oncol 2000;18:2522-2528.
21. FARESE AM, YANG BB, ROSKOS L, STEAD RB, MACVITTIE TJ. Pegfilgrastim, a sustained-duration form of Filgrastim, significantly improves neutrophil recovery after autologous marrow transplantation in rhesus macaques. Bone Marrow Transplant 2003;32:399-404.
22. JAGASIA MH, GREER JP, MORGAN DS, MINEISHI S, KASSIM AA, RUFFNER KL, CHEN H, SCHUENING FG. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study. Bone Marrow Transplant 2005;35:1165-1169.
23. STABER PB, HOLUB R, LINKESCH W, SCHMIDT H, NEUMEISTER P. Fixed dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2005;35:889-893.
24. MUSSO M, PORRETTO F, CRESCIMANNO A, POLIZZI V, SCALONE R, MONDELLO F. Filgrastim (G-csf) versus Pegfilgrastim after autologous peripheral haematopoietic stem cell transplant in patients with haematological malignancies. Bone Marrow Transplant 2005;35(Suppl. 2):S331.
25. MUSTO P, SCALZULLI PR, MELILLO L. Peg-Filgrastim after autologous peripheral blood stem cell transplantation in haematological malignancies. Blood 2004;104:384b.
26. MARTINO M, MORABITO F, MESSINA G, IRRERA G, PUCCI G, IACOPINO P. Fractionated infusions of cryopreserved stem cells may prevent DMSO-induced major cardiac complications in graft recipients. Haematologica 1996;81:59-61.
27. FELD R. Multinational cooperation in trials and guidelines dealing with febrile neutropenia. Int J Antimicrob Agents 2000;16:185-187.
28. SOUSSAIN C, MAREC L, ABARAH W, ALLARD C, MALLEK H, ITANI C. Pegfilgastrim after high-dose chemotherapy and autologous peripheral blood stem cells transplantation. A single-centre experience in 15 patients. Blood 2004;104:139b.
29. VANSTRAELEN G, FRERE P, NGIRABACU MC, WILLEMS E, FILLET G, BEGUIN Y. Pegfilgrastim compared with Filgrastim after autologous haematopoietic peripheral blood stem cell transplantation. Exp Hematol 2006;34:382-388.
30. MORABITO F, MARTINO M, STELITANO C, et al. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica 2002;87:1192-1199.